<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00792376</url>
  </required_header>
  <id_info>
    <org_study_id>00045-2008</org_study_id>
    <secondary_id>1-47-12225-05-1</secondary_id>
    <nct_id>NCT00792376</nct_id>
  </id_info>
  <brief_title>&quot;NSAIDs in Acute Achilles Tendinopathy: Effect on Pain Control, Leg Stiffness and Functional Recovery in Athletes&quot;</brief_title>
  <official_title>&quot;NSAIDs in Acute Achilles Tendinopathy: Effect on Pain Control, Leg Stiffness and Functional Recovery in Athletes&quot;</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Argentine Tennis Association</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Argentine Tennis Association</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate etoricoxib efficacy in pain control, leg stiffness&#xD;
      and functional recovery of patients suffering acute Achilles tendinopathy.&#xD;
&#xD;
      It is hypothesized that etoricoxib (120mg orally/day/7 days) efficacy is not inferior to&#xD;
      diclofenac (150mg orally /day/7 days) for pain control in subjects suffering acute Achilles&#xD;
      tendinopathy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2009</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The pre-defined primary efficacy endpoint of the study is a 100-mm pain visual analog scale (P-VAS), where 0= no pain; 100= extreme pain.</measure>
    <time_frame>1 week</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The secondary study endpoints includes: the VISA-A Questionnaire, the Achilles Tendinopathy Scoring System (ATSS), PGART using a 5-point Likert scale and leg functional stiffness.</measure>
    <time_frame>1 week</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Achilles Tendinopathy</condition>
  <arm_group>
    <arm_group_label>etoricoxib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>etoricoxib (ETO) group (n=28) treated with etoricoxib 120 mg/day orally for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>diclofenac</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>diclofenac (DIC) group (n=28) received diclofenac 150 mg/day/7 days orally.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoricoxib</intervention_name>
    <description>etoricoxib (ETO) group (n=28) treated with etoricoxib 120 mg/day orally for 7 days</description>
    <arm_group_label>etoricoxib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>diclofenac</intervention_name>
    <description>diclofenac (DIC) group (n=28) received diclofenac 150 mg/day/7 days orally.</description>
    <arm_group_label>diclofenac</arm_group_label>
    <arm_group_label>etoricoxib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients are eligible if they are male between 18 and 50 years of age and they suffer&#xD;
             acute Achilles tendinopathy (&lt;2 weeks). Diagnosis of Achilles tendinopathy is made by&#xD;
             means of activity-related achillodynia, morning stiffness or pain, painful one-legged&#xD;
             jumping test, tenderness and decreased sports performance (26). Subjects' age, race,&#xD;
             affected tendon (right, left), activity, height and weight will be recorded.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients are excluded from the study if they have:&#xD;
&#xD;
          -  Prior lower limb surgery or major trauma.&#xD;
&#xD;
          -  Bilateral Achilles tendinopathy.&#xD;
&#xD;
          -  History of lower limb radiculo-neuropathy or miopathy.&#xD;
&#xD;
          -  Hypersensitivity to any NSAIDs.&#xD;
&#xD;
          -  Used analgesic agents (NSAIDs, salicilates, narcotic) within 1 week&#xD;
&#xD;
          -  Concurrent medical/arthritic disease (e.g. gout, lupus, rheumatoid arthritis).&#xD;
&#xD;
          -  Other concurrent medical conditions including diabetes, hypertension, angina or&#xD;
             congestive heart failure, ischaemic cardiopathy, malabsorption, morbid - Personal&#xD;
             history of renal dysfunction, hepatic dysfunction or anemia&#xD;
&#xD;
          -  Used corticosteroids, clopidogrel bisulphate, rifampin, quinolon antibiotics,&#xD;
             antiepileptics, muscle relaxants, warfarin, ticlopidine, glucosamine, condroitin&#xD;
             sulphate for &lt; 6 months prior to the study start. Patients taking low dose aspirin&#xD;
             (100 mg) for cardioprotective benefit will be also excluded. Any other medication&#xD;
             consumption will be considered by the investigator and the Ethical Committee.&#xD;
&#xD;
          -  Any other condition which, in the opinion of the investigator, could confound the&#xD;
             study results or pose a risk to the patient (for example, co-morbid conditions for&#xD;
             which NSAIDs are contraindicated).&#xD;
&#xD;
          -  History of psychotic illness, dementia or depression&#xD;
&#xD;
          -  History of drug or alcohol abuse or dependence.&#xD;
&#xD;
          -  Participated in any previous NSAIDs study and received active treatment, or in an&#xD;
             investigational trial within 30 days prior to the first visit.&#xD;
&#xD;
          -  Inability to communicate or to cooperate with the investigator.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Argentine Tennis Association</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <study_first_submitted>November 14, 2008</study_first_submitted>
  <study_first_submitted_qc>November 14, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 17, 2008</study_first_posted>
  <last_update_submitted>August 2, 2013</last_update_submitted>
  <last_update_submitted_qc>August 2, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 6, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Argentine Tennis Association</investigator_affiliation>
    <investigator_full_name>Javier Maquirriain</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>NSAID</keyword>
  <keyword>tendon</keyword>
  <keyword>pain</keyword>
  <keyword>stiffness</keyword>
  <keyword>Achilles</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tendinopathy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diclofenac</mesh_term>
    <mesh_term>Etoricoxib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

